期刊
TRANSLATIONAL STROKE RESEARCH
卷 8, 期 2, 页码 157-164出版社
SPRINGER
DOI: 10.1007/s12975-016-0493-3
关键词
Acute ischemic stroke; Dipeptidyl peptidase IV (DPP IV); Fibroblast activation protein (FAP); Stroke evolution; Stroke outcome; Stroke severity
资金
- University of Antwerp Research Fund [FFB3551]
- Institute Born-Bunge
- Antwerp Biobank
- Interuniversity Attraction Poles (IAP) program of the Belgian Science Policy Office
- Flemish Government Methusalem excellence program, Belgium
Dipeptidyl peptidase IV (DPPIV) inhibition may be a promising therapeutic strategy for acute stroke treatment, given its potential to prolong the biological half-life of neuroprotective substrates. A related protease, fibroblast activation protein (FAP), was recently shown to inactivate the same substrates. Therefore, it should also be investigated as a potential target in stroke. The study aimed to investigate whether stroke severity and outcome correlate with DPPIV and FAP activities and their kinetics shortly after acute ischemic stroke. DPPIV and FAP activities were analyzed in the serum of 50 hyperacute stroke patients at admission, 1 day, 3 days, and 7 days after stroke onset and in 50 age-matched healthy controls. This was done as part of the Middelheim's Interdisciplinary Stroke Study. DPPIV activity tended to increase shortly after stroke compared to the control population. DPPIV and FAP activities steadily decreased in the first week after stroke onset. Higher infarct volumes (>= 5 ml) and a more severe stroke (NIHSS >7) at admission were correlated with a stronger decrease in the activities of both enzymes. Moreover, these patients more often developed a progressive stroke, were more often institutionalized. Patients with a stronger increase in DPPIV activity at admission and decrease in the activity of both DPPIV and FAP during the first week after stroke onset had a more severe stroke and worse short-term outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据